FirstSun Capital Bancorp enters July with a fresh analyst upgrade on one side of the ledger and a meaningful week-on-week jump in short interest on the other — an unusual pairing for a stock that just logged a 4.7% weekly gain.
The standout this week is the analyst action. Raymond James upgraded FSUN to Strong Buy from Outperform on July 1, lifting the price target to $47 from $44. That's the most constructive call on the stock since coverage began, and it lands with the shares at $38.78 — implying roughly 21% upside to the new target. The broader analyst community has been directionally positive throughout 2026, with Stephens and Piper Sandler both maintaining Overweight ratings, even as they trimmed targets modestly after Q1 results in late April. The consensus mean target of $43.50 predates the Raymond James move and will likely shift higher once updated. Overall, the Street is leaning bullish: bears focus on NIM underperformance relative to peers and credit risk in the commercial real estate book, while bulls point to the loan portfolio's expansion to 87% of earning assets and the prospect of index inclusion driving incremental volume.
Short interest tells a more complicated story. Bears added to positions aggressively this week — short interest rose nearly 15% over seven days to 4.5% of the free float, the sharpest weekly build in the past six weeks. That followed a period of relative stability through most of May and early June, when short interest hovered near 1.07–1.09 million shares. The jump to 1.25 million shares is notable, particularly coming in the same week the stock rallied and earned a high-profile upgrade. Yet the borrow market offers no amplification: availability is loose at roughly 990%, meaning there are nearly ten shares available to lend for every one already borrowed. Cost to borrow has eased over the past month to just 0.47%, near the low end of its recent range. The lending setup does not suggest squeeze conditions — there's ample room for new shorts to enter without facing punishing borrow costs.
Options positioning adds little to the story. The put/call ratio is essentially unchanged at 0.0017, a level it has held for most of the past six weeks, and the z-score is near zero. For a mid-cap regional bank with limited options liquidity, the near-flat PCR confirms that derivatives traders have no particular directional view. The 52-week high on the PCR was 0.30 — the current reading is a fraction of that, suggesting options markets are not being used to hedge or express a bearish view right now.
Valuation multiples remain compressed but stable. The price-to-earnings multiple is running near 8.8x, drifting slightly lower over the past week and month. Price-to-book is below 1x at 0.82, up modestly over 30 days. For context, the forward earnings yield has edged higher to around 11.4%, which is consistent with a bank trading at a discount to book while the market waits for margin recovery. The ORTEX short score has been drifting higher over the past week, reaching 42.3 from 38.8 a week ago — still in the middle of the range, but moving in the direction that reflects the recent short interest build rather than any structural squeeze risk.
Among correlated peers, FSUN's 4.7% weekly gain was the strongest in the group. GABC and CPF rose 3.4% and 3.3% respectively, while FCF was the laggard at 1.7%. BY nearly matched FSUN at 4.7%, though the two share limited fundamental overlap. The broad regional bank cohort moved higher in tandem, suggesting macro tailwinds rather than stock-specific catalysts drove most of the week's gains — which makes the Raymond James upgrade and the simultaneous short build the two angles most worth tracking into the Q2 earnings print scheduled for July 27.
What to watch: whether the short interest build persists into the earnings date, or whether the Raymond James upgrade and continued price strength prompt covering ahead of the July 27 Q2 report.
See the live data behind this article on ORTEX.
Open FSUN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
